A New Phase of Biopharmaceuticals

PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved biotherapeutics for the treatment of serious rare diseases, with an initial focus on cardiopulmonary indications. We are leveraging our proprietary elastin-like polypeptide technology to advance a pipeline of drug candidates with the potential for less frequent dosing and better patient compliance.